Senate Committee Advances Bill to Ban "Pay-for-Delay" Drug Deals That Keep Generics Off Market
The Senate must act next: a Senate floor vote.
No action since April 2025
This bill’s path across every version that has carried it.
How this policy affects specific groups of people
Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Read twice and referred to the Committee on the Judiciary.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
The Preserve Access to Affordable Generics and Biosimilars Act would limit “pay-for-delay” deals in which companies compensate generic manufacturers to delay the entrance of their products into the market. Sen. Amy Klobuchar explained the bill targets agreements raising serious competitive concerns.
Klobuchar and Grassley teamed up on the Preserve Access to Affordable Generics and Biosimilars Act, which they say would end “anti-competitive behavior” — specifically, deals struck between branded companies and generic companies to keep a generic, or a biosimilar, off the market.
U.S. Senators Amy Klobuchar and Chuck Grassley reintroduced legislation that would make it illegal for brand-name drug manufacturers to pay-off other drug manufacturers to keep generic versions of brand-name drugs off the market, citing FTC reports on the high cost of these settlements.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Preserve Access to Affordable Generics and Biosimilars Act
Analysis generated by AI. Always verify with official sources.